| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.UROLOGY.2010.04.042 |
| P698 | PubMed publication ID | 20630573 |
| P2093 | author name string | Akinori Sato | |
| Keiichi Ito | |||
| Makoto Sumitomo | |||
| Tomohiko Asano | |||
| Takako Asano | |||
| Akio Horiguchi | |||
| P2860 | cites work | Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation | Q24649964 |
| Sorafenib in advanced clear-cell renal-cell carcinoma | Q28282767 | ||
| Acetylation and deacetylation of non-histone proteins | Q29619636 | ||
| The human transcriptome map: clustering of highly expressed genes in chromosomal domains | Q29622859 | ||
| Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer | Q33377144 | ||
| Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer | Q33379343 | ||
| Histone deacetylases, transcriptional control, and cancer | Q33926323 | ||
| Transcriptional control at regulatory checkpoints by histone deacetylases: molecular connections between cancer and chromatin | Q34188997 | ||
| Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code | Q34193936 | ||
| A Detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis | Q34249812 | ||
| Histone acetylation and disease | Q34298969 | ||
| Renal-cell carcinoma | Q34394356 | ||
| Vorinostat (NSC# 701852) in patients with relapsed non-small cell lung cancer: a Wisconsin Oncology Network phase II study | Q34632964 | ||
| Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation | Q34956099 | ||
| Histone deacetylase (HDAC) inhibitor activation of p21WAF1 involves changes in promoter-associated proteins, including HDAC1 | Q36017473 | ||
| Epigenetic therapy of cancer: past, present and future | Q36399557 | ||
| A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study | Q36528653 | ||
| Histone deacetylase inhibitors: molecular mechanisms of action | Q36908440 | ||
| Ritonavir blocks AKT signaling, activates apoptosis and inhibits migration and invasion in ovarian cancer cells | Q37215121 | ||
| Second generation hybrid polar compounds are potent inducers of transformed cell differentiation. | Q37550149 | ||
| Ritonavir induces endoplasmic reticulum stress and sensitizes sarcoma cells toward bortezomib-induced apoptosis | Q39958648 | ||
| Synergistic interaction of the histone deacetylase inhibitor SAHA with the proteasome inhibitor bortezomib in mantle cell lymphoma | Q40051317 | ||
| SAHA induces apoptosis in hepatoma cells and synergistically interacts with the proteasome inhibitor Bortezomib | Q40160625 | ||
| Valproate inhibition of histone deacetylase 2 affects differentiation and decreases proliferation of endometrial stromal sarcoma cells | Q40229841 | ||
| An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells | Q43420338 | ||
| Efficient intervention of growth and infiltration of primary adult T-cell leukemia cells by an HIV protease inhibitor, ritonavir | Q43705976 | ||
| Activity of suberoylanilide hydroxamic Acid against human breast cancer cells with amplification of her-2. | Q46689478 | ||
| XIAP expression is an independent prognostic marker in clear-cell renal carcinomas. | Q53366105 | ||
| Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma | Q83195713 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | ritonavir | Q422618 |
| P304 | page(s) | 764.e7-13 | |
| P577 | publication date | 2010-07-13 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | Combination of suberoylanilide hydroxamic acid and ritonavir is effective against renal cancer cells | |
| P478 | volume | 76 |
| Q37115414 | HDAC inhibitors in kidney development and disease |
| Q27025984 | Histone deacetylase inhibitors and epigenetic modifications as a novel strategy in renal cell carcinoma |
| Q40179484 | Nelfinavir and Ritonavir Kill Bladder Cancer Cells Synergistically By Inducing Endoplasmic Reticulum Stress |
| Q38742176 | Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells |
| Q35444159 | The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies |
| Q35052701 | The novel histone deacetylase inhibitor, N-hydroxy-7-(2-naphthylthio) hepatonomide, exhibits potent antitumor activity due to cytochrome-c-release-mediated apoptosis in renal cell carcinoma cells |
| Q48136812 | Therapeutic effects of histone deacetylase inhibitors on kidney disease. |
| Q27000542 | Trials with 'epigenetic' drugs: an update |
Search more.